ConductScience.org, home

Paper17547827

Adherence-resistance relationships to combination HIV antiretroviral therapy.

Bangsberg DR and 2 others. Curr HIV/AIDS Rep, 2007. Cited by 137 papers, by iCite.

Cite this record

ConductScience Library. Adherence-resistance relationships to combination HIV antiretroviral therapy. Papers, record 17547827. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17547827

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adherence-resistance relationships to combination HIV antiretroviral therapy.
PubMed
Journal
Curr HIV/AIDS Rep
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
137
iCite
Relative citation ratio, by iCite
4.08
iCite
Revised in PubMed
2019-11-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bangsberg DRDavid R
2Kroetz DLDeanna L
3Deeks SGSteven G

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Retroviral AgentsMajor topic
Drug Resistance, ViralMajor topic
HIV InfectionsMajor topic
Patient ComplianceMajor topic
Drug Administration Schedule
Drug Therapy, Combination
Humans
Pharmacogenetics
Protease Inhibitors

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 MH054907NIMH NIH HHSUnited StatesR01MH054907PubMed and NIHNIH RePORTER
AA 015287NIAAA NIH HHSUnited StatesK24AA015287PubMed and NIHNIH RePORTER
GM 61390NIGMS NIH HHSUnited StatesU01GM061390PubMed and NIHNIH RePORTER
MH 54907NIMH NIH HHSUnited StatesR01MH054907PubMed and NIHNIH RePORTER
U19GM061390NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00608569Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected AdultsBackground

Source ClinicalTrials.gov

Download CSV of trials

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115750116Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.J Clin Microbiol2005https://conductscience.org/library/papers/15750116PubMed
215668854Efavirenz intoxication due to slow hepatic metabolism.Clin Infect Dis2005https://conductscience.org/library/papers/15668854PubMed
315115831Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.N Engl J Med2004https://conductscience.org/library/papers/15115831PubMed
416267764Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.J Infect Dis2005https://conductscience.org/library/papers/16267764PubMed
516249701Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).J Acquir Immune Defic Syndr2005https://conductscience.org/library/papers/16249701PubMed
611437654Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.Virology2001https://conductscience.org/library/papers/11437654PubMed
711752705In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.J Gen Virol2002https://conductscience.org/library/papers/11752705PubMed
811502341Preventing antiretroviral anarchy in sub-Saharan Africa.Lancet2001https://conductscience.org/library/papers/11502341PubMed
915127346Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.Clin Infect Dis2004https://conductscience.org/library/papers/15127346PubMed
1010570031Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.Drug Metab Dispos1999https://conductscience.org/library/papers/10570031PubMed
1114702153Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.J Infect Dis2004https://conductscience.org/library/papers/14702153PubMed
1216249703Selective drug taking during combination antiretroviral therapy in an unselected clinic population.J Acquir Immune Defic Syndr2005https://conductscience.org/library/papers/16249703PubMed
1316355337Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.Clin Infect Dis2006https://conductscience.org/library/papers/16355337PubMed
1416511415Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.AIDS2006https://conductscience.org/library/papers/16511415PubMed
1514693536
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrob Agents Chemother2004https://conductscience.org/library/papers/14693536PubMed
1614694092Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.J Virol2004https://conductscience.org/library/papers/14694092PubMed
1715486844Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.Clin Infect Dis2004https://conductscience.org/library/papers/15486844PubMed
1817457090Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.AIDS2007https://conductscience.org/library/papers/17457090PubMed
1916946457Update of the drug resistance mutations in HIV-1: Fall 2006.Top HIV Med2006https://conductscience.org/library/papers/16946457PubMed
2015622315Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS2004https://conductscience.org/library/papers/15622315PubMed

See all 80 referencesDownload CSV of references

Cited by102

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.

PMIDTitleJournalYearIn PapersSource
41847579Critical level of food insecurity and nonadherence to antiretroviral therapy among adults living with HIV.Public Health Action2026https://conductscience.org/library/papers/41847579PubMed
40544855Predictors of treatment-emergent resistance to dolutegravir.Lancet HIV2025https://conductscience.org/library/papers/40544855PubMed
38905197LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment.PLoS One2024https://conductscience.org/library/papers/38905197PubMed
38796507Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use.Commun Med (Lond)2024https://conductscience.org/library/papers/38796507PubMed
38140667A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Viruses2023https://conductscience.org/library/papers/38140667PubMed
36350211The risk of drug resistance during long-acting antimicrobial therapy.Proc Biol Sci2022https://conductscience.org/library/papers/36350211PubMed
35797374Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients.PLoS One2022https://conductscience.org/library/papers/35797374PubMed
35444410Adherence to HIV Antiretroviral Therapy Among Pregnant and Breastfeeding Women, Non-Pregnant Women, and Men in Burkina Faso: Nationwide Analysis 2019-2020.Patient Prefer Adherence2022https://conductscience.org/library/papers/35444410PubMed
35213648Qualitative systems mapping for complex public health problems: A practical guide.PLoS One2022https://conductscience.org/library/papers/35213648PubMed
34905404Substance Use-Related Intentional Nonadherence to Antiretroviral Therapy Among Young Adults Living with HIV.AIDS Patient Care STDS2022https://conductscience.org/library/papers/34905404PubMed
34567064Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China.Front Genet2021https://conductscience.org/library/papers/34567064PubMed
34473060Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.Elife2021https://conductscience.org/library/papers/34473060PubMed
33451356Validation of multiplex PCR sequencing assay of SIV.Virol J2021https://conductscience.org/library/papers/33451356PubMed
33226999Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.PLoS One2020https://conductscience.org/library/papers/33226999PubMed
33105694Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.Molecules2020https://conductscience.org/library/papers/33105694PubMed
32324724Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.MMWR Recomm Rep2020https://conductscience.org/library/papers/32324724PubMed
32286041Target-Based Design of Promysalin Analogues Identifies a New Putative Binding Cleft in Succinate Dehydrogenase.ACS Infect Dis2020https://conductscience.org/library/papers/32286041PubMed
32011966The Effect of an Integrated Health System Specialty Pharmacy on HIV Antiretroviral Therapy Adherence, Viral Suppression, and CD4 Count in an Outpatient Infectious Disease Clinic.J Manag Care Spec Pharm2020https://conductscience.org/library/papers/32011966PubMed
31488063Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study.BMC Infect Dis2019https://conductscience.org/library/papers/31488063PubMed
30668713Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.J Antimicrob Chemother2019https://conductscience.org/library/papers/30668713PubMed

See all 102 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17547827

GET https://conductscience.org/api/papers/v1/17547827/references?page=2